# Therini Bio, Inc.

> Therini Bio is a clinical-stage biotechnology company developing fibrin-targeting immunotherapies for neurodegenerative and retinal diseases driven by vascular dysfunction. Founded in 2019 on the neurovascular research of Dr. Katerina Akassoglou at UCSF and the Gladstone Institutes, the company's lead antibody THN391 selectively blocks fibrin's inflammatory epitope to halt chronic neuroinflammation without interfering with normal blood clotting. Backed by roughly $145M in total funding from investors including Eli Lilly, Sanofi Ventures, Merck's MRL Ventures and the Dementia Discovery Fund, Therini is advancing THN391 into Phase 1b trials for Alzheimer's disease and diabetic macular edema.

- **Founded:** 2019
- **Headquarters:** South San Francisco, California, United States
- **Founders:** Katerina Akassoglou (Scientific Founder; Director, Center for Neurovascular Brain Immunology at UCSF & Gladstone Institutes)
- **Team size:** ~15 employees
- **Products:** THN391, THN622
- **Notable:** Advanced a first-in-class fibrin-targeting antibody (THN391) from academic discovery into human clinical trials., Raised roughly $145M in total funding, including a $75M combined Series A., Reported positive Phase 1a results: well-tolerated, clean hematological/coagulation profile, no anti-drug antibodies, monthly-dosing pharmacokinetics.

## Products & services

- **THN391** — Lead candidate: a first-in-class, high-affinity humanized monoclonal antibody that selectively binds fibrin's inflammatory epitope to block fibrin-mediated neuroinflammation without interfering with coagulation. In Phase 1b for Alzheimer's disease and diabetic macular edema.
- **THN622** — Second candidate: a bispecific antibody combining fibrin targeting with VEGF inhibition, uniting the anti-VEGF standard of care for retinal disease with fibrin-driven neuroinflammation blockade in a single molecule.

## Achievements

- Advanced a first-in-class fibrin-targeting antibody (THN391) from academic discovery into human clinical trials.
- Raised roughly $145M in total funding, including a $75M combined Series A.
- Reported positive Phase 1a results: well-tolerated, clean hematological/coagulation profile, no anti-drug antibodies, monthly-dosing pharmacokinetics.
- Attracted strategic investment from three major pharma venture arms (Lilly, Merck's MRL, Sanofi Ventures).
- Selected to present Phase 1a data at the Alzheimer's Association International Conference (AAIC) 2025.

## Latest updates

- **2025-07** — Therini Bio presented positive THN391 Phase 1a data at the Alzheimer's Association International Conference (AAIC 2025) in Toronto.
- **2025-05** — Closed a $39M Series A extension led by new investors Angelini Ventures and Apollo Health Ventures, bringing the Series A total to $75M.
- **2025-04** — Announced positive Phase 1a trial results for THN391 in healthy volunteers - well-tolerated with a clean coagulation profile.
- **2023-04** — Raised $36M Series A to develop fibrin-targeted therapies for neurodegenerative and retinal diseases.

## Links

- Website: https://therinibio.com
- LinkedIn: http://www.linkedin.com/company/therinibio

---

Profile page: https://yespress.io/therini-bio-inc
Published by YesPress — https://yespress.io
Last updated: 2026-07-10